The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer

被引:270
作者
Eisenhauer, Eric L.
Abu-Rustum, Nadeem R.
Sonoda, Yukio
Levine, Douglas A.
Poynor, Elizabeth A.
Aghajanian, Carol
Jarnagin, William R.
DeMatteo, Ronald P.
D'Angelica, Michael I.
Barakat, Richard R.
Chi, Dennis S.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, Hepatobiliary Serv, New York, NY 10021 USA
关键词
ovarian cancer; cytoreduction; upper abdominal; survival;
D O I
10.1016/j.ygyno.2006.06.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. To determine the survival impact of adding extensive upper abdominal surgical cytoreduction to standard surgical techniques for advanced ovarian cancer. Methods. The records of all patients with stages ITIC-IV epithelial ovarian cancer who underwent primary surgery at our institution from 1998 to 2003 were reviewed. The cohort was divided into 3 groups. Group I patients required extensive upper abdominal surgery, such as diaphragm peritonectomy/resection, resection of parenchymal liver or porta hepatis disease and/or splenectomy with or without distal pancreatectomy, to achieve optimal cytoreduction (residual disease <= 1 cm). Group 2 patients were optimally cytoreduced by standard surgical techniques, including hysterectomy, oophorectomy, omentectomy, and bowel resection. Group 3 patients were suboptimally cytoreduced. Primary outcome measures were response to primary chemotherapy, progress ion-free survival, and overall survival. Results. The cohort of 262 patients was divided as follows: Group 1, 57 patients; Group 2, 122 patients; and Group 3, 83 patients. The median follow-up was 36 months (range, 1-94 months). Frequency of clinical complete response in Groups 1, 2, and 3 was 82%, 78%, and 57%, respectively. The median progression-free survival for Groups 1, 2, and 3 was 24, 23, and 11 months, respectively. Progression-free survival for Groups 1 and 2 were equivalent (P=0.53) and were significantly longer than for Group 3 (P < 0.001). The median overall survival was 84 and 38 months for Groups 2 and 3, respectively, and had not been reached for Group 1 by 68 months. Patients in Group 1 had equivalent overall survival to patients in Group 2 (P=0.74) and improved survival over patients in Group 3 (P < 0.001). Prognostic factors significant on multivariate analysis included stage, optimal status, and ascites. Conclusions. Patients requiring extensive upper abdominal procedures to achieve optimal cytoreduction demonstrated a similar initial response, progression-free survival, and overall survival to patients optimally cytoreduced by standard surgical techniques. The presence of bulky upper abdominal disease alone did not appear to indicate poor tumor biology. This initial maximal surgical effort was associated with improved survival in patients who would have otherwise been suboptimally cytoreduced. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1083 / 1090
页数:8
相关论文
共 47 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]   Aggressive surgical effort and improved survival in advanced-stage ovarian cancer [J].
Aletti, GD ;
Dowdy, SC ;
Gostout, BS ;
Jones, MB ;
Stanhope, CR ;
Wilson, TO ;
Podratz, KC ;
Cliby, WA .
OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) :77-85
[3]  
Allen D. G., 1995, European Journal of Gynaecological Oncology, V16, P349
[4]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[5]   Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma - a Gynecologic Oncology Group Study [J].
Bloss, JD ;
Brady, MF ;
Liao, SY ;
Rocereto, T ;
Partridge, EE ;
Clarke-Pearson, DL .
GYNECOLOGIC ONCOLOGY, 2003, 89 (01) :148-154
[6]   Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group [J].
Bookman, MA ;
McGuire, WP ;
Kilpatrick, D ;
Keenan, E ;
Hogan, WM ;
Johnson, SW ;
ODwyer, P ;
Rowinsky, E ;
Gallion, HH ;
Ozols, RF .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1895-1902
[7]   Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer [J].
Bristow, RE ;
Montz, FJ ;
Lagasse, LD ;
Leuchter, RS ;
Karlan, BY .
GYNECOLOGIC ONCOLOGY, 1999, 72 (03) :278-287
[8]   Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator [J].
Bristow, RE ;
Montz, FJ .
GYNECOLOGIC ONCOLOGY, 2001, 83 (01) :39-48
[9]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[10]   Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach [J].
Chi, DS ;
Franklin, CC ;
Levine, DA ;
Akselrod, F ;
Sabbatini, P ;
Jarnagin, WR ;
DeMatteo, R ;
Poynor, EA ;
Abu-Rustum, NR ;
Barakat, RR .
GYNECOLOGIC ONCOLOGY, 2004, 94 (03) :650-654